EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY 4.0

A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma

Yousef Zakharia, Donghyun Kim iD, Michele Freesmeier, Melanie Frees, Sarah Mott, Varun Monga, Douglas Laux, Asad Javed, John Rieth iD, John Smestad iD, Mohammed Milhem

Cancer · 2026

DOI: 10.1002/cncr.70326 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer, 2026. Verfasst von Yousef Zakharia und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa Health Care, Iowa City, I…. Hauptthemen laut MEDLINE: Anilides, Antibodies, Monoclonal, Humanized, Melanoma, Pyridines. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Exelixis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pembrolizumab is approved for advanced cutaneous melanoma (aCM). Cabozantinib, an oral multi‐tyrosine kinase inhibitor, has demonstrated antitumor activity as monotherapy or in combination with anti‐PD‐1 therapy in malignancies. The objective of this study was to determine the safety and efficacy of cabozantinib and pembrolizumab for patients with aCM.

Methods

This phase 1b/2 study enrolled 28 patients with unresectable aCM. In phase 1b, escalating dose levels of cabozantinib (20 mg, 40 mg, and 60 mg) were administered concurrently with pembrolizumab 200 mg intravenously every 3 weeks using a 3 + 3 design to determine recommended phase 2 dose (RP2D). In phase 2, patients received cabozantinib at RP2D in combination with pembrolizumab using a Simon 2 stage design. Primary end point of phase 2 was overall response rate (ORR). Secondary end points included disease control rate, progression‐free survival (PFS), and overall survival (OS).

Results

Phase 1b enrolled eight patients, cabozantinib 40 mg daily dose level was selected as RP2D. Response rate in stage 1 exceeded predefined criteria for proceeding to expansion phase; however, phase 2 was terminated after 20 patients due to low accrual in the setting of evolving standard of care. Among all treated patients, the most common grade ≥3 toxicities were hypertension ( n = 10, 36%), hypokalemia ( n = 5, 18%), hypophosphatemia ( n = 4, 14%), and ALT elevation ( n = 4, 14%). Among 20 patients treated in phase 2, ORR was 45%, median PFS was 6.6 months, and median OS was 29.5 months.

Conclusions

Cabozantinib and pembrolizumab combination was explored in treatment‐naive aCM. Toxicity was consistent with known profiles, but discontinuation rates were notable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnilidesAntibodies, Monoclonal, HumanizedMelanomaPyridinesSkin NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleAgedMiddle AgedAdultAged, 80 and overCutaneous Malignant Melanoma

Stichwörter der Autor:innen

combination therapyimmune checkpoint inhibitorskin cancer

Substanzen

AnilidesAntibodies, Monoclonal, HumanizedPyridinespembrolizumabcabozantinib

Autor:innen und Institutionen

  • Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa Health Care, Iowa City, Iowa, USA.
  • Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona, USA.
  • University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, USA.
  • Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Physician-Scientist Training Program, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.

ORCID-Profile: Donghyun Kim, John Rieth, John Smestad

Förderung

  • Exelixis

Zitieren

APA

Zakharia, Y., Kim, D., Freesmeier, M., Frees, M., Mott, S., Monga, V., Laux, D., Javed, A., Rieth, J., Smestad, J., & Milhem, M. (2026). A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma. Cancer. https://doi.org/10.1002/cncr.70326

Vancouver

Zakharia Y, Kim D, Freesmeier M, Frees M, Mott S, Monga V, et al. A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma. Cancer. 2026. doi:10.1002/cncr.70326

BibTeX
@article{Zakharia2026,
  author = {Zakharia, Yousef and Kim, Donghyun and Freesmeier, Michele and Frees, Melanie and Mott, Sarah and Monga, Varun and Laux, Douglas and Javed, Asad and Rieth, John and Smestad, John and Milhem, Mohammed},
  title = {A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70326}
}
Kostenlos starten →